Inferior base Nasolabial Flap in Oral submucous Fibrosis: case report

Authors

  • Ankur Rathaur Rama Dental College Hospital & Research Centre, Rama University, Mandhana, Kanpur, Uttar Pradesh- India 209217 Author
  • Prasanna Kumar P Rama Dental College Hospital & Research Centre, Rama University, Mandhana, Kanpur, Uttar Pradesh- India 209217 Author
  • Ankita Raj,Aathira Madhu Rama Dental College Hospital & Research Centre, Rama University, Mandhana, Kanpur, Uttar Pradesh- India 209217 Author
  • Akash Tiwari Rama Dental College Hospital & Research Centre, Rama University, Mandhana, Kanpur, Uttar Pradesh- India 209217 Author
  • Tuba Jamal Rama Dental College Hospital & Research Centre, Rama University, Mandhana, Kanpur, Uttar Pradesh- India 209217 Author

Abstract

 Oral submucous fibrosis (OSMF) is a chronic, insidious, progressive oral mucosal disease affecting the oral cavity, pharynx, and upper digestive tract, causing stiffness of the oral mucosa, restricted mouth opening, and impaired ability to eat, speak or care for oral hygiene. Serious complication is the risk of development of oral carcinoma. Different treatment modalities like medical, surgical, physical therapy or combination are used to improve the condition of the patient. Surgical treatment is usually indicated in late and irreversible stage of the disease. Successful use of nasolabial flap in the management of OSMF is presented. 

Downloads

Download data is not yet available.

References

Oral submucous fibrosis: Current concepts on aetiology and management - A

review. Khan S, Sinha A, Kumar S, Iqbal H. J Indian Acad Oral Med

Radiol. 2018;30:407–411.

An alternative pathogenetic pathway for oral submucous fibrosis (OSMF)

Rajendran R, Vijayakumar T, Vasudevan DM. Med Hypotheses. 1989;30:35–37. [

Increased severity of oral submucous fibrosis in young Pakistani men. Merchant

AT, Haider SM, Fikree FF. Br J Oral Maxillofac Surg. 1997;35:284–287.

Betel quid without tobacco as a risk factor for oral precancers. Jacob BJ, Straif K,

Thomas G, et al. Oral Oncol. 2004;40:697–704. [

Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids.

Harvey W, Scutt A, Meghji S, Canniff JP. Arch Oral Biol. 1986;31:45–49.

An in-vitro comparison of human fibroblasts from normal and oral submucous

fibrosis tissue. Meghji S, Scutt A, Harvey W, Canniff JP. Arch Oral

Biol. 1987;32:213–215. .

Immunolocalization of cytokines and growth factors in oral submucous fibrosis.

Haque MF, Harris M, Meghji S, Barrett AW. Cytokine. 1998;10:713–719. .

Augmented mRNA expression of tissue inhibitor of metalloproteinase-1 in buccal

mucosal fibroblasts by arecoline and safrole as a possible pathogenesis for oral

submucous fibrosis. Shieh DH, Chiang LC, Shieh TY. Oral Oncol. 2003;39:728–

.

Oral submucous fibrosis. A review. Cox SC, Walker DM. Aust Dent

J. 1996;41:294–299. .

Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of

gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible

mechanisms for oral submucous fibrosis. Chang YC, Yang SF, Tai KW, Chou MY,

Hsieh YS. Oral Oncol. 2002;38:195–200. .

Oral submucous fibrosis: review on mechanisms of malignant transformation.

Ekanayaka RP, Tilakaratne WM. Oral Surg Oral Med Oral Pathol Oral

Radiol. 2016;122:192–199. .

Current protocols in the management of oral submucous fibrosis: An update.

Arakeri G, Rai KK, Boraks G, et al. J Oral Pathol Med. 2017;46:418–423. .

Oral submucous fibrosis. Pindborg JJ, Sirsat SM. Oral Surg Oral Med Oral

Pathol. 1966;22:764–779. .

Etiology of oral submucous fibrosis with special reference to the role of areca nut

chewing. Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Pindborg JJ, Mehta FS. J

Oral Pathol Med. 1995;24:145–152. .

Oral submucous fibrosis: review on aetiology and pathogenesis. Tilakaratne WM,

Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S. Oral Oncol. 2006;42:561–

.

Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis. Haque MF,

Meghji S, Nazir R, Harris M. J Oral Pathol Med. 2001;30:12–21. .

Aloe vera in treatment of oral submucous fibrosis: A systematic review and metaanalysis. Al-Maweri SA, Ashraf S, Lingam AS, Alqutaibi A, Abdulrab S, Alaizari N,

Halboub E. J Oral Pathol Med. 2019;48:99–107. .

Possible action mechanism for curcumin in pre-cancerous lesions based on serum

and salivary markers of oxidative stress. Rai B, Kaur J, Jacobs R, Singh J. J Oral

Sci. 2010;52:251–256. .

An approach to management of oral submucous fibrosis: current status and review

of literature. Fry RR, Goyal S, Pandher PK, Chawla

JP. http://journalcra.com/sites/default/files/issue-pdf/7001.pdf Int J Curr

Res. 2014;6:10598–10604. [Google Scholar]

Treatment of oral submucous fibrosis with ErCr: YSGG laser. Chaudhary Z,

Verma M, Tandon S. https://www.ijdr.in/text.asp?2011/22/3/472/87073. Indian J

Dent Res. 2011;22:472–474. .

Oral submucous fibrosis: Newer proposed classification with critical updates in

pathogenesis and management strategies. Passi D, Bhanot P, Kacker D, Chahal D,

Atri M, Panwar Y. Natl J Maxillofac Surg. 2017;8:89–94. [PMC free article] .

Oral submucous fibrosis as a precancerous condition. Pindborg JJ, Murti PR,

Bhonsle RB, Gupta PC, Daftary DK, Mehta FS. Scand J Dent Res. 1984;92:224–

.

Malignant transformation rate in oral submucous fibrosis over a 17-year period.

Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Community

Dent Oral Epidemiol. 1985;13:340–341. .

Proposed clinical classification for oral submucous fibrosis. More CB, Das S,

Patel H, Adalja C, Kamatchi V, Venkatesh R. Oral Oncol. 2012;48:200–202. .

Oral submucous fibrosis: a new concept in surgical management. Report of 100

cases. Khanna JN, Andrade NN. Int J Oral Maxillofac Surg. 1995;24:433–439. .

Salivary copper and zinc levels in oral pre-malignant and malignant lesions.

Ayinampudi BK, Narsimhan M. J Oral Maxillofac Pathol. 2012;16:178–182. [PMC

free article] .

Oral submucosal fibrosis--a preventable disease. Jayanthi V, Probert CS, Sher KS,

Mayberry JF. Gut. 1992;33:4–6.[PMC free article] .

Incidence and early forms of oral submucous fibrosis. Pindborg JJ, Bhonsle RB,

Murti PR, Gupta PC, Daftary DK, Mehta FS. Oral Surg Oral Med Oral

Pathol. 1980;50:40–44. .

Malignant transformation of oral submucous fibrosis in Taiwan: A nationwide

population-based retrospective cohort study. Yang PY, Chen YT, Wang YH, Su NY,

Yu HC, Chang YC. J Oral Pathol Med. 2017;46:1040–1045..

Treatment of oral submucous fibrosis by collagenase: effects on oral opening and

eating function. Lin HJ, Lin JC. Oral Dis. 2007;13:407–413. .

Oral submucous fibrosis: study of 1000 cases from central India. Hazarey VK,

Erlewad DM, Mundhe KA, Ughade SN. J Oral Pathol Med. 2007;36:12–17. .

Oral submucous fibrosis patients have altered levels of cytokine production.

Haque MF, Meghji S, Khitab U, Harris M. J Oral Pathol Med. 2000;29:123–128. .

Aloe vera in the treatment for oral submucous fibrosis - a preliminary study.

Sudarshan R, Annigeri RG, Sree Vijayabala G. J Oral Pathol Med. 2012;41:755–

.

Curcumin in oral mucosal lesions: An update. Rai A, Kumar A, Hasan S, Saeed

S. Asian J Pharm Clin Res. 2019;12:32–43. [Google Scholar]

Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis.

Rajendran R, Rani V, Shaikh

S. https://www.ijdr.in/text.asp?2006/17/4/190/29865. Indian J Dent

Res. 2006;17:190–198. .

Oral submucous fibrosis--a new treatment regimen. Gupta D, Sharma SC. J Oral

Maxillofac Surg. 1988;46:830–833. .

Oral submucous fibrosis--treatment with hyalase. Kakar PK, Puri RK,

Venkatachalam VP. J Laryngol Otol. 1985;99:57–59. .

Management of oral submucous fibrosis: an overview. Angadi PV, Rao S. Oral

Maxillofac Surg. 2010;14:133–142..

Is buccal fat pad a better option than nasolabial flap for reconstruction of intraoral

defects after surgical release of fibrous bands in patients with oral submucous

fibrosis? A pilot study: a protocol for the management of oral submucous fibrosis. Rai

A, Datarkar A, Rai M. J Craniomaxillofac Surg. 2014;42:0–6. .

Oral submucous fibrosis: a clinico-histopathological study in Chennai. Kiran

Kumar K, Saraswathi TR, Ranganathan K, Uma Devi M, Elizabeth J. Indian J Dent

Res. 2007;18:106–111. .

Clinical evaluation of Er,Cr:YSGG and GaAlAs laser therapy for treating dentine

hypersensitivity: A randomized controlled clinical trial. Yilmaz HG, KurtulmusYilmaz S, Cengiz E, Bayindir H, Aykac Y. J Dent. 2011;39:249–254..

Autologous bone marrow concentrate (Mononuclear Stem Cell) therapy in the

treatment of oral submucous fibrosis. Seshadri S, Kailasam S, Elangovan S, Ravi VR,

Sarkar S. J Indian Acad Oral Med Radiol. 2013;25:1–4. [Google Scholar]

Oncogene amplification in squamous cell carcinoma of the oral cavity. Saranath

D, Panchal RG, Nair R, et al. Jpn J Cancer Res. 1989;80:430–437. [PMC free

article] .

Ras mutations in United Kingdom examples of oral malignancies are infrequent.

Chang SE, Bhatia P, Johnson NW, Morgan PR, McCormick F, Young B, Hiorns

L. Int J Cancer. 1991;48:409–412. .

A transforming Kirsten ras oncogene in an oral squamous carcinoma. Howell RE,

Wong FS, Fenwick RG. J Oral Pathol Med. 1990;19:301–305. .

Depigmentation of oral mucosa as the earliest possible manifestation of oral

submucous fibrosis in Sri Lankan preschool children. Sitheeque M, Ariyawardana A,

Jayasinghe R, Tilakaratne W. J Investig Clin Dent. 2010;1:156–

Downloads

Published

2022-02-28

Issue

Vol. 8 No. 1 (2022): 8 (1) 2022

Section

Articles

License

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

Rathaur, A., Kumar P, P., Raj,Aathira Madhu, A., Tiwari, A., & Jamal, T. (2022). Inferior base Nasolabial Flap in Oral submucous Fibrosis: case report. History of Medicine, 8(1). http://13.200.237.241/HOM/index.php/medicine/article/view/302